Cargando…
Exploring treatment with Ribociclib alone or in sequence/combination with Everolimus in ER(+)HER2(−)Rb wild-type and knock-down in breast cancer cell lines
BACKGROUND: Breast cancer (BC) is the second most common type of cancer worldwide. Among targeted therapies for Hormone Receptor-positive (HR(+)) and Human Epidermal growth factor Receptor 2-negative (HER2(−)) BC, the Cyclin-Dependent Kinases (CDK4/6) are targeted by inhibitors such as Ribociclib (R...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678099/ https://www.ncbi.nlm.nih.gov/pubmed/33213401 http://dx.doi.org/10.1186/s12885-020-07619-1 |